MIRA Pharmaceuticals grants 50,000 stock options

MIRA PHARMACEUTICALS, INC. director Matthew Paul Del Giudice reported receiving a grant of stock options.

Accepted by SEC EDGAR 06/15/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

MIRA PHARMACEUTICALS, INC. director Matthew Paul Del Giudice reported receiving a grant of stock options. He was awarded 50,000 stock options to buy common stock at an exercise price of $0.94 per share, expiring on June 12, 2036.

The options were granted under the company’s 2022 Omnibus Incentive Plan. According to the vesting schedule, 50% of the options vest six months after the June 12, 2026 grant date, and the remaining half vests on the one-year anniversary of that date.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Del Giudice Matthew Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 50,000 contracts (Direct)

Holdings Before and After: Stock Options (right to buy), 0 to 50,000 contracts (Direct)

Footnotes (3)

1. F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.
2. F2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
3. F3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

Key Figures

Stock options granted: 50,000 options Exercise price: $0.94 per share Options expiration: June 12, 2036 +4 more

7 metrics

Stock options granted 50,000 options Grant to director on June 12, 2026

Exercise price $0.94 per share Equals closing price on June 12, 2026

Options expiration June 12, 2036 Expiration date of granted stock options

Underlying shares 50,000 common shares Shares issuable upon exercise of options

Post-transaction derivative holdings 50,000 options Total options held after grant

Initial vesting 50% after six months First tranche vesting from June 12, 2026 grant

Final vesting 50% after one year Remaining tranche vests one year after grant date

Key Terms

Stock Options (right to buy), exercise price, 2022 Omnibus Incentive Plan, vest, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"at an exercise price of $0.94 each"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2022 Omnibus Incentive Plan financial

"pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated"

vest financial

"50% of the options vest on the six-month anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: 2036-06-12T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MIRA (MIRA) report for Matthew Paul Del Giudice?

MIRA director Matthew Paul Del Giudice reported receiving 50,000 stock options as compensation. These options allow him to buy common stock at a $0.94 exercise price and were granted under the company’s 2022 Omnibus Incentive Plan with time-based vesting.

How many stock options were granted to the MIRA director and at what price?

He was granted 50,000 stock options with an exercise price of $0.94 per share. This price equals the closing price of MIRA’s common stock on June 12, 2026, according to the footnotes accompanying the Form 4 filing.

What is the vesting schedule for the 50,000 MIRA stock options?

The 50,000 options vest in two equal blocks over 12 months. Half vests on the six-month anniversary of the June 12, 2026 grant date, and the remaining half vests on the one-year anniversary, subject to the terms of the 2022 Omnibus Incentive Plan.

When do Matthew Paul Del Giudice’s MIRA stock options expire?

The granted stock options expire on June 12, 2036. This gives the director a 10-year window from the grant date to exercise vested options at the $0.94 per share exercise price, in accordance with the plan terms described in the Form 4.

How many derivative securities does the MIRA director hold after this Form 4 transaction?

After this transaction, the director holds 50,000 stock options according to the Form 4. These options are derivative securities linked to an equivalent number of MIRA common shares, subject to vesting and exercisable at a $0.94 per share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Del Giudice Matthew Paul

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.94(1)	06/12/2026		A		50,000		(2)	06/12/2036	Common Stock	50,000	$0	50,000(3)	D

Explanation of Responses:

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

	/s/ Matthew Paul Del Giudice	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)